People: Aravive Inc (ARAV.OQ)

ARAV.OQ on NASDAQ Stock Exchange Global Select Market

23 Oct 2020
Change (% chg)

$0.06 (+1.16%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Rangwala, Reshma 

Dr. Reshma Rangwala M.D., Ph.D. serves as Chief Medical Officer of the Company. Dr. Rangwala has more than a decade of experience in oncology and drug development. Previously, she served as Vice President, Medical, at Genmab where she led the clinical development program for a first-in-class antibody drug conjugate and managed clinical strategy, protocol development, data monitoring, data analysis, study report authoring, and biologic licensing application preparations. Prior to that, she served as Executive Clinical Director at Merck & Co., where she was involved in the clinical development of KEYTRUDA in non-small cell lung cancer and gynecologic malignancies. She received her B.S. in Biology from Duke University and her M.D./Ph.D. from the University of Cincinnati College of Medicine. Dr. Rangwala completed her internal medicine residency at Barnes Jewish Hospital in St. Louis, MO and her medical oncology fellowship at the Hospital of the University of Pennsylvania.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --